Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
View/ Open
Author
Lim, Laurence S
Ng, Wei Yan
Mathur, Ranjana
Wong, Doric
Wong, Edmund YM
Yeo, Ian
Cheung, Chui Ming Gemmy
Lee, Shu Yen
Wong, Tien Yin
Papakostas, Thanos D
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.2147/OPTH.S81523Metadata
Show full item recordCitation
Lim, L. S., W. Y. Ng, R. Mathur, D. Wong, E. Y. Wong, I. Yeo, C. M. G. Cheung, et al. 2015. “Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab.” Clinical Ophthalmology (Auckland, N.Z.) 9 (1): 1715-1718. doi:10.2147/OPTH.S81523. http://dx.doi.org/10.2147/OPTH.S81523.Abstract
Background: The purpose of this study was to determine if eyes with diabetic macular edema (DME) unresponsive to ranibizumab or bevacizumab would benefit from conversion to aflibercept. Methods: This study was conducted as a retrospective chart review of subjects with DME unresponsive to ranibizumab and/or bevacizumab and subsequently converted to aflibercept. Results: In total, 21 eyes from 19 subjects of mean age 62±15 years were included. The majority of subjects were male (63%). The median number of ranibizumab or bevacizumab injections before switching to aflibercept was six, and the median number of aflibercept injections after switching was three. Median follow-up was 5 months after the switch. Mean central foveal thickness (CFT) was 453.52±143.39 mm immediately prior to the switch. Morphologically, intraretinal cysts were present in all cases. Mean CFT after the first injection decreased significantly to 362.57±92.82 mm (Wilcoxon signed-rank test; P<0.001). At the end of follow-up, the mean CFT was 324.17±98.76 mm (P<0.001). Mean visual acuity was 0.42±0.23 logMAR just prior to the switch, 0.39±0.31 logMAR after one aflibercept injection, and 0.37±0.22 log-MAR at the end of follow-up. The final visual acuity was significantly better than visual acuity before the switch (P=0.04). Conclusion: Eyes with DME unresponsive to multiple ranibizumab/bevacizumab injections demonstrate anatomical and visual improvement on conversion to aflibercept.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577250/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856858
Collections
- HMS Scholarly Articles [17922]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)